Spok Holdings, Inc. SPOK R2KR3KPHARMA
Company Overview
Spok Holdings, Inc., through its subsidiary, Spok, Inc., engages in the healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. Its products and services enhance workflows for clinicians and support administrative compliance. The company delivers clinical information to care teams when and where it matters to enhance patient outcomes; and provides GenA Pager, a one-way alphanumeric pager. It offers subscriptions to one-way or two-way messaging services, as well as alphanumeric pagers that are configurable to support unencrypted or encrypted operation; and ancillary services, such as voicemail, and equipment loss or maintenance protection services, as well as sells devices to resellers who lease or resell them to their subscribers. The company provides Spok Care Connect suite products for contact centers, clinical alerting and notification, mobile communications and messaging, and public safety notifications. In addition, it provides professional, software license updates, and product support services, as well as sells third-party equipment. It serves businesses, professionals, management personnel, medical personnel, field sales personnel and service forces, members of the construction industry and construction trades, real estate brokers and developers, sales and services organizations, specialty trade organizations, manufacturing organizations, and government agencies. The company was formerly known as USA Mobility, Inc. and changed its name to Spok Holdings, Inc. in July 2014. Spok Holdings, Inc. was founded in 1986 and is headquartered in Plano, Texas.
Why Investors Should Care
Trades at a P/E of 18.8, below the sector median of 25.2.
Operating margin of 19.9% supports profitability.
Offers a dividend yield of 11.06%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $139.71M (+1.5% YoY); net profit $15.88M.
- Trailing 12 Months Year-on-year growth — revenue -1.9%, earnings -10.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -4.5%, profit CAGR -8.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -4.46% |
| 1 Year: | -1.90% |
Compounded Profit Growth
| 5 Years: | -8.65% |
| 1 Year: | -10.40% |
Stock Price Performance
| 1 Year: | -37.10% |
| 6 Months: | -7.03% |
| 3 Months: | +2.94% |
| 1 Month: | -2.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.45 · Neutral
P/E of 18.79 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 11.06%.
- Generates positive free cash flow.
CONS
- Revenue declined at -4.5% CAGR over 5 years.
- Earnings shrank at -8.6% CAGR over 5 years.
- Trading 37.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPOK Spok Holdings, Inc. R2KR3KPHARMA | 10.71 | 18.79 | $224.03M | 11.06% | 12.55% | 8.42% | -4.46% | -8.65% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 41.44M | 42.33M | 43.64M | 43.77M | 43.11M | 40.63M | 42.48M | 43.26M | 41.76M | 39.52M | 39.45M | 39.55M | 37.27M | 35.74M | 37.69M | 37.48M | 36.04M | 35.72M | 35.85M | 33.83M | 33.71M | 33.74M | 33.18M | 36.46M | 35.43M | 34.91M | 33.98M | 34.87M | 36.29M | 35.69M | 33.87M | 33.23M | 35.01M |
| Operating Income | 5.62M | 6.66M | 6.55M | 5.80M | 5.62M | 6.03M | 4.70M | 1.38M | 2.41M | 3.33M | 3.59M | 584.00K | -2.35M | -1.56M | 149.00K | 1.11M | -1.99M | -2.69M | -12.24M | -4.11M | 3.16M | 2.73M | -24.45M | -1.74M | -1.61M | -3.56M | -8.67M | 2.41M | 3.54M | 4.72M | 6.21M | 6.21M | 4.89M | 4.47M | 4.96M | 6.02M | 5.39M | 4.36M | 2.44M | 5.42M |
| Net Income | 3.38M | 4.22M | 68.73M | 3.44M | 3.45M | 4.06M | 3.03M | 854.00K | 1.50M | 3.73M | 21.38M | 345.00K | -1.17M | -840.00K | 189.00K | 742.00K | -670.00K | -1.33M | -9.51M | -4.54M | 3.76M | 3.17M | -46.61M | -2.30M | -719.00K | -7.21M | -7.21M | 1.92M | 2.92M | 3.12M | 4.73M | 4.45M | 4.24M | 3.42M | 3.66M | 5.20M | 4.55M | 3.20M | 1.99M | 4.12M |
| Diluted EPS | 0.16 | 0.20 | 3.53 | 0.17 | 0.17 | 0.20 | - | - | 0.07 | - | - | - | -0.05 | - | - | - | - | -0.07 | - | -0.24 | 0.20 | 0.16 | -2.44 | -0.12 | -0.04 | -0.13 | -0.37 | 0.10 | 0.15 | 0.15 | 0.23 | 0.22 | 0.21 | 0.17 | 0.18 | 0.25 | 0.22 | 0.15 | 0.09 | 0.20 |
| R&D Expense | - | - | - | 2.91M | 3.21M | 3.65M | - | 4.11M | 4.66M | 5.00M | - | 5.74M | 6.18M | 5.93M | - | 6.17M | 6.81M | 7.44M | - | 5.45M | 2.75M | 3.46M | - | 4.44M | 4.16M | 4.06M | 6.50M | 2.62M | 2.22M | 2.49M | 2.85M | 2.56M | 2.95M | 3.18M | 2.83M | 3.09M | 3.02M | 2.99M | 3.46M | 3.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 289.71M | 233.25M | 233.69M | 219.70M | 209.75M | 200.27M | 189.63M | 179.56M | 171.18M | 169.47M | 160.29M | 148.18M | 142.15M | 134.53M | 139.03M | 137.65M | 139.71M |
| Operating Income | 57.41M | 57.18M | 51.83M | 45.73M | 45.49M | 28.15M | 25.10M | 22.15M | 10.71M | -3.17M | -15.81M | -22.66M | -27.72M | 238.00K | 21.23M | 18.96M | 19.71M |
| Net Income | 67.56M | 77.90M | 83.79M | 26.98M | 27.53M | 20.75M | 80.25M | 13.98M | -15.31M | -1.48M | -10.77M | -44.23M | -22.18M | 21.86M | 15.67M | 14.96M | 15.88M |
| Diluted EPS | 2.90 | 3.45 | 3.72 | 1.20 | 1.25 | 0.94 | 3.98 | - | - | - | -0.56 | -2.32 | -1.14 | 1.09 | 0.77 | 0.73 | 0.75 |
| R&D Expense | - | - | - | 8.90M | 8.70M | 9.50M | 10.28M | 13.47M | 18.70M | 24.46M | 27.54M | 15.74M | 17.51M | 13.62M | 10.68M | 11.69M | 12.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 230.66M | 354.42M | 322.63M | 326.90M | 337.89M | 386.43M | 388.09M | 348.00M | 327.71M | 319.87M | 277.29M | 248.15M | 244.48M | 227.68M | 217.10M | 206.11M |
| Total Equity | 140.74M | 158.80M | 184.39M | 247.59M | 251.42M | 269.95M | 279.06M | 329.56M | 322.09M | 290.53M | 274.55M | 250.09M | 199.63M | 172.71M | 171.10M | 163.77M | 154.75M | 146.38M |
| Cash & Equivalents | 75.03M | 109.59M | 129.22M | 53.66M | 61.05M | 89.08M | 107.87M | 109.33M | 121.83M | 103.18M | 83.34M | 47.36M | 48.73M | 44.58M | 35.75M | 31.99M | 29.14M | 25.28M |
| Long Term Debt | - | - | 0 | 28.25M | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 46.27M | 97.62M | 71.21M | 56.95M | 58.83M | 56.87M | 66.00M | 57.48M | 53.16M | 69.78M | 76.68M | 74.46M | 73.38M | 63.91M | 62.36M | 59.73M |
| Current Liabilities | - | - | 34.48M | 56.57M | 60.73M | 46.83M | 49.76M | 47.16M | 56.33M | 48.34M | 44.95M | 51.18M | 57.44M | 55.00M | 54.43M | 48.01M | 48.77M | 49.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 101.86M | 79.42M | 82.44M | 72.88M | 50.46M | 41.56M | 41.84M | 37.55M | 15.52M | 10.31M | 11.69M | 26.16M | 7.97M | 6.46M | 26.18M | 28.92M | 28.95M |
| Investing Cash Flow | -17.06M | -6.66M | -134.65M | -12.66M | -10.12M | -7.61M | -5.57M | -8.23M | -9.17M | -5.83M | -30.22M | -14.57M | -225.00K | 11.26M | -3.42M | -3.21M | -3.05M |
| Financing Cash Flow | -50.24M | -53.13M | -23.35M | -52.83M | -12.31M | -15.15M | -32.81M | -16.72M | -25.00M | -24.28M | -17.15M | -10.37M | -11.75M | -26.22M | -26.68M | -28.54M | -29.79M |
| Capital Expenditure | -17.23M | -8.74M | -7.95M | -9.99M | -10.41M | -7.61M | -5.57M | -6.25M | -9.21M | -5.92M | -4.84M | -3.46M | -4.39M | -3.78M | -3.42M | -3.21M | -3.75M |
| Free Cash Flow | 84.63M | 70.68M | 74.48M | 62.89M | 40.05M | 33.95M | 36.27M | 31.30M | 6.30M | 4.40M | 6.86M | 22.71M | 3.58M | 2.68M | 22.77M | 25.71M | 25.20M |
| Share Buybacks | 4.74M | 8.89M | 0 | 8.06M | 0 | 4.33M | 15.01M | 6.49M | 10.02M | 13.48M | 6.58M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 19.8% | 24.5% | 22.2% | 20.8% | 21.7% | 14.1% | 13.2% | 12.3% | 6.3% | -1.9% | -9.9% | -15.3% | -19.5% | 0.2% | 15.3% | 13.8% | 14.1% |
| Net Margin % | 23.3% | 33.4% | 35.9% | 12.3% | 13.1% | 10.4% | 42.3% | 7.8% | -8.9% | -0.9% | -6.7% | -29.8% | -15.6% | 16.2% | 11.3% | 10.9% | 11.4% |
| ROE % | 42.5% | 42.2% | 33.8% | 10.7% | 10.2% | 7.4% | 24.3% | 4.3% | -5.3% | -0.5% | -4.3% | -22.2% | -12.8% | 12.8% | 9.6% | 9.7% | 10.8% |
| ROCE % | - | 29.1% | 17.4% | 17.5% | 16.2% | 9.8% | 7.4% | 6.7% | 3.6% | -1.1% | -5.9% | -10.3% | -14.4% | 0.1% | 11.8% | 11.3% | 12.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.22% | 1.72M | $18.31M |
| 2 | Renaissance Technologies, LLC | 5.49% | 1.15M | $12.23M |
| 3 | Vanguard Capital Management LLC | 4.17% | 872.36K | $9.29M |
| 4 | Dimensional Fund Advisors LP | 3.43% | 717.62K | $7.64M |
| 5 | Geode Capital Management, LLC | 2.85% | 595.84K | $6.35M |
| 6 | State Street Corporation | 2.25% | 471.58K | $5.02M |
| 7 | HighTower Advisors, LLC | 1.62% | 339.89K | $3.62M |
| 8 | Qube Research & Technologies Ltd | 1.37% | 287.62K | $3.06M |
| 9 | Goldman Sachs Group Inc | 1.35% | 281.98K | $3.00M |
| 10 | Vanguard Portfolio Management LLC | 1.31% | 273.28K | $2.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPOK
Spok Holdings (SPOK) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOMEM3THpPVE1ENDBLaFZGQllnMmN5U2NSQjVLU2xrMGtpQzA5RWMySU0tWVFlZFFxUzVYcDNKcjBJTGtrN0pxM1NqbUxVN243NS1RNTZiSWlSSURaRzVWR2R6akktSTgydEdGVm9MS3lRQUhBQzN2Y09TUzFpUTctT3hUMkIzY3ZURHdnb3…
Understanding the Setup: (SPOK) and Scalable Risk - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNZWhaQzREWFFSVlltSUdNU3JfWE1MeVV1bnItVUVxZm9JRW9XSG8tMVFjRS02bVN5dWZSWm9FbDZ1TTJsTFduclhjcWpSYndLenhuOFdjMVUwVTFja0hOQmxscG5BdWFOTWU5OHhfNTlQTG1KVkdLVUt6SWg5VEd2V3Y1Vm1OMnJJRXRpWT…
Spok Holdings (SPOK) Stock Faces Dividend Doubts Despite Record Adjusted EBITDA - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQVVpHN1JJd0xoZXRMY0U2MUFYUmJBUktraEJiVzRFMkZieFNaWThXS2E0UjNQRXRlOENPTTNPbDV4bmVPNHVmQmY5dEVZLVFyeEFMVWtZZFBSU29aVzU3cVJmSnVFektKWjdQY192LWVyTFFaOTVrc3NpRzI3c1RVX3lwUFZPV1FINEg2UG…
Spok Holdings Inc (NASDAQ: SPOK) Share Price, SPOK Stock News, SPOK Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE82T0lZcjk4bzRON2RfaUFKcDRWUFFZRXMzbERRQlV3MFFGbXRYcnBObTBvcncycDQ0MEV3ZHNxaXJ2RjNSTEhSaUxtLU5LRWMxY0ZOVDNn?oc=5" target="_blank">Spok Holdings Inc (NASDAQ: SPOK) Share Price, SPOK …
Spok Q2 Net Income Falls To $4.1 Million As Revenue Slips - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNUXlEZFlPZzNDRkpHVFp5bXhPaU9tU2pHY3BndGlzcUhqV0lFaDNaWGVha0ZhMV9aeTVmcjgwTXZyTUpQRjZxeEU5d1lQclFFR3MtdWtFVG1mck8zVndrTWZ0eHRsanQ2T1RCdUE1NXEyTi03OWFEUl9lOTlGRVFad3kxYWcwWm1acVo0ZE…
Spok (NASDAQ:SPOK) Stock Price Crosses Above 200-Day Moving Average - Should You Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNU08wOEpKU0VjbTlfNjlEbzdNcVVrZGJ1c0ZXcHZ4N0RnSVYzdmlIZmFZaTNFRy1WbE9DUmtGSlFJWUpoTDVvOTZmT1p6cjdYaVZwdmZ5T3JZMm10Vl8xRk5TUlRhdG5DbDBESjFRYVlEQW5nVjdZakhYYTl1VkdnU2RjekZxTDBVbjQ3Nn…
SPOK — Frequently Asked Questions
What is the current share price of Spok Holdings, Inc. (SPOK)?
As of 2026-09-07 16:24 PDT, Spok Holdings, Inc. (SPOK) trades at $10.71 on NasdaqGS. Its 52-week range is $9.95 to $17.03.
What is the market capitalisation of SPOK?
Spok Holdings, Inc. (SPOK) has a market capitalisation of $224.03M on NasdaqGS.
What is the P/E ratio of SPOK?
SPOK trades at a trailing price-to-earnings (P/E) ratio of 18.79. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.71.
Does SPOK pay a dividend?
Spok Holdings, Inc. (SPOK) currently offers a dividend yield of 11.06%.
What is the return on equity (ROE) of SPOK?
SPOK has a return on equity (ROE) of 8.42%. Its return on capital employed (ROCE) is 12.55%.
Is SPOK a good stock to buy?
This page provides a data-driven analysis of Spok Holdings, Inc. (SPOK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.